首页|脱敏治疗药物在预致敏肾移植中的应用及进展

脱敏治疗药物在预致敏肾移植中的应用及进展

Applications and advances of desensitizing therapeutic agents in pre-sensitized renal transplantation

扫码查看
肾移植是治疗终末期肾脏病的主要方式之一,不同中心报道的移植肾10年存活率在75%~80%。研究认为,肾移植是目前降低肾功能衰竭全因死亡率的最佳治疗方式,可明显改善受者生存率与生活质量。预致敏受者由于体内预存有抗人类白细胞抗原抗体,其移植术后发生排斥的风险远高于非致敏受者,但目前随着各类脱敏技术的应用,此类受者的移植率以及术后受者/移植肾存活率已逐渐升高,致敏不再是肾移植的禁忌证。本文主要就预致敏肾移植脱敏治疗药物的进展进行综述和展望。 Kidney transplantation (KT) is one primary treatment of end-stage renal disease (ESRD). As reported by different centers, 10-year survival rate of transplanted kidneys fluctuates from 75% to 80%. Capable of reducing all-cause mortality in renal failure, KT can significantly improve survival rate and quality-of-life of ESRD patients. The risk of post-transplant rejection is much higher in pre-sensitised recipients than in non-sensitised ones due to the pre-existing anti-human leukocyte antigen antibodies. However, with a rapid development of various desensitisation techniques, transplantation rate and postoperative human/kidney survival rate of recipients have been greatly enhanced. And presensitisation is no longer a contraindication to KT. This review focused upon the latest advances in desensitisation therapeutic agents for pre-sensitised KT.
Kidney transplantation (KT) is one primary treatment of end-stage renal disease (ESRD). As reported by different centers, 10-year survival rate of transplanted kidneys fluctuates from 75% to 80%. Capable of reducing all-cause mortality in renal failure, KT can significantly improve survival rate and quality-of-life of ESRD patients. The risk of post-transplant rejection is much higher in pre-sensitised recipients than in non-sensitised ones due to the pre-existing anti-human leukocyte antigen antibodies. However, with a rapid development of various desensitisation techniques, transplantation rate and postoperative human/kidney survival rate of recipients have been greatly enhanced. And presensitisation is no longer a contraindication to KT. This review focused upon the latest advances in desensitisation therapeutic agents for pre-sensitised KT.

PresensitisationKidney transplantationDesensitisation treatment

王佳婷、胡雨婷、丁洁、寿张飞

展开 >

浙江大学医学院,杭州 310030

浙江中医药大学浙江树人学院,杭州 310053

预致敏 肾移植 脱敏治疗

2024

中华器官移植杂志
中华医学会

中华器官移植杂志

CSTPCD
影响因子:0.574
ISSN:0254-1785
年,卷(期):2024.45(3)